Researchers from the Vanderbilt University School of Medicine in Nashville, Tenn., compared the risk of death among patients on long-acting opioid therapy for chronic pain with that of patients on analgesic anticonvulsant or low-dose cyclic antidepressant treatments.
They found patients on opioids had a risk of all-cause mortality that was 1.6 times greater than the mortality of the control group patients. More than two-thirds of the deaths were not related to unintentional overdose; and more than half of those deaths were cardiovascular deaths.
“These findings should be considered when evaluating harms and benefits of treatment,” the authors wrote.
More articles on opioids:
Senate panel approves $261M funding bill to fight opioid epidemic
5 states where opioid overdose antidote prices rose the most
AHA, CDC create new patient resource on prescription opioids
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
